Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany
- 21 October 2014
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 108 (2) , 123-130
Abstract
Background and Objectives: We estimated and compared the residual risks due to window‐period donations for pooled and apheresis platelets in Germany using a modification of a previously described statistical model. This model directly utilizes the reported interdonation intervals before a positive donation and reflects in this aspect the look‐back procedures used in haemovigilance.Materials and Methods: Data from the German National Blood Donor Surveillance System for the years 2006–2012, including reports about donations from repeat donors with confirmed positive test results for HIV, HCV and HBV, were used to estimate the risk of undetected infectious units for both pooled and apheresis platelets.Results: Demographics of whole‐blood and apheresis donors differed in age, gender, catchment area and interdonation interval. These differences impact on the prevalence and incidence of transfusion relevant infections and consequently the residual risk. The estimates for the residual risks for pooled and apheresis platelets were comparable. For HIV, there was no significant difference, for HCV apheresis platelets had a lower residual risk, whereas pooled platelets had a lower risk for undetected HBV infections.Conclusion: These findings do not support calls for a shift to an apheresis platelets‐only policy in Germany.Keywords
This publication has 31 references indexed in Scilit:
- Human immunodeficiency virus prevalence, incidence, and residual risk of transmission by transfusions at Retrovirus Epidemiology Donor Study‐II blood centers in BrazilTransfusion, 2011
- Report on Notifications Pursuant to §21 German Transfusion Act for 2008 and 2009Transfusion Medicine and Hemotherapy, 2011
- Disparate risks and effects of pooled whole blood-derived vs. apheresis platelet production require an integral view on the blood supply.Vox Sanguinis, 2010
- Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?Vox Sanguinis, 2010
- Report on Notifications Pursuant to §21 German Transfusion Act for 2007Transfusion Medicine and Hemotherapy, 2010
- The German Haemovigilance System–reports of serious adverse transfusion reactions between 1997 and 2007Transfusion Medicine, 2009
- Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus‐1, hepatitis C virus, and hepatitis B virusTransfusion, 2008
- A General Change of the Platelet Transfusion Policy from Apheresis Platelet Concentrates to Pooled Platelet Concentrates is Associated with a Sharp Increase in Donor Exposure and Infection RatesTransfusion Medicine and Hemotherapy, 2008
- A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donorsTransfusion, 2005
- A statistical method for the estimation of window-period risk of transfusion-transmitted HIV in donor screening under non-steady stateBiostatistics, 2002